The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
|Videos|April 19, 2011
Ted Okon on the Challenges of the VBID
Author(s)Ted Okon
Ted Okon the Executive Director of the Community Oncology Alliance (COA) Discusses the Challenges of the Value-Based Insurance Design
Advertisement
Ted Okon the Executive Director of the Community Oncology Alliance (COA) Discusses the Challenges of the Value-Based Insurance Design
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
OncLive Weekly News Quiz (10/9/2026): Did You Miss Crucial Colon Cancer, Myeloma, Breast Cancer, and Lung Cancer Updates?
4
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
5